KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Paul Smith of Orasis Pharmaceuticals discusses phase 3 data for the CSF-1 eye drop for presbyopia treatment following its new drug application submission to the FDA.
“We’re encouraged to report that CSF-1 does indeed hit its mark,” he said. “We are excited to be next in this new and emerging category.”